Tags

Type your tag names separated by a space and hit enter

Potential pharmacological agents for COVID-19.
Indian J Public Health. 2020 Jun; 64(Supplement):S112-S116.IJ

Abstract

A novel coronavirus disease 2019 (COVID-19) infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) first emerged in December 2019 in Wuhan, China, has become a global pandemic. Currently, the management of COVID-19 infection is mainly supportive. Several clinical trials worldwide are evaluating several drugs approved for other indications, as well as multiple investigational agents for the treatment and prevention of COVID-19. Here, we give a brief overview of pharmacological agents and other therapies which are under investigation as treatment options or adjunctive agents for patients infected with COVID-19 and for chemoprophylaxis for the prevention of COVID-19 infection. At the time of writing this commentary, there is no peer-reviewed published evidence from randomized clinical trials of any pharmacological agents improving outcomes in COVID-19 patients. However, it was reported that remdesivir an investigational antiviral agent hastens clinical recovery, but a study is yet to be published in peer-reviewed medical journal.

Authors+Show Affiliations

Professor, Department of Pharmacology, V. P. Chest Institute, University of Delhi, Delhi, India.Assistant Professor, Department of Internal Medicine, Division of Infectious Diseases, Washington University School of Medicine, Saint Louis, Missouri, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32496239

Citation

Kotwani, Anita, and Sumanth Gandra. "Potential Pharmacological Agents for COVID-19." Indian Journal of Public Health, vol. 64, no. Supplement, 2020, pp. S112-S116.
Kotwani A, Gandra S. Potential pharmacological agents for COVID-19. Indian J Public Health. 2020;64(Supplement):S112-S116.
Kotwani, A., & Gandra, S. (2020). Potential pharmacological agents for COVID-19. Indian Journal of Public Health, 64(Supplement), S112-S116. https://doi.org/10.4103/ijph.IJPH_456_20
Kotwani A, Gandra S. Potential Pharmacological Agents for COVID-19. Indian J Public Health. 2020;64(Supplement):S112-S116. PubMed PMID: 32496239.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential pharmacological agents for COVID-19. AU - Kotwani,Anita, AU - Gandra,Sumanth, PY - 2020/6/5/entrez PY - 2020/6/5/pubmed PY - 2020/6/18/medline KW - Adjunctive therapy KW - coronavirus disease 2019 KW - investigational antiviral agents KW - potential pharmacological agents KW - severe acute respiratory syndrome coronavirus 2 SP - S112 EP - S116 JF - Indian journal of public health JO - Indian J Public Health VL - 64 IS - Supplement N2 - A novel coronavirus disease 2019 (COVID-19) infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) first emerged in December 2019 in Wuhan, China, has become a global pandemic. Currently, the management of COVID-19 infection is mainly supportive. Several clinical trials worldwide are evaluating several drugs approved for other indications, as well as multiple investigational agents for the treatment and prevention of COVID-19. Here, we give a brief overview of pharmacological agents and other therapies which are under investigation as treatment options or adjunctive agents for patients infected with COVID-19 and for chemoprophylaxis for the prevention of COVID-19 infection. At the time of writing this commentary, there is no peer-reviewed published evidence from randomized clinical trials of any pharmacological agents improving outcomes in COVID-19 patients. However, it was reported that remdesivir an investigational antiviral agent hastens clinical recovery, but a study is yet to be published in peer-reviewed medical journal. SN - 0019-557X UR - https://www.unboundmedicine.com/medline/citation/32496239/Potential_pharmacological_agents_for_COVID_19_ L2 - http://www.ijph.in/article.asp?issn=0019-557X;year=2020;volume=64;issue=6;spage=112;epage=116;aulast=Kotwani DB - PRIME DP - Unbound Medicine ER -